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Preeclampsia is a global maternal health burden due to its high maternal mortality and morbidity, 
especially in developing countries, which appears in Indonesia.1 Two hundred and sixty-threemillion 
people occupying a large area of Indonesia gave rise the problem of the high maternal mortality rate 
of 305/100,000 deliveries where preeclampsia (PE) and eclampsia (E) stand out as a massive health care 
problem in Indonesia with some teaching hospital rates approximately ranged 22-25 %.2 Although 
the precise pathophysiology of PE remains obscure,3,4 It has beenstrongly suggested that placental 
dysfunction with released factors containing excessive oxidative molecules, trophoblast debris and pro-
infl ammatory cytokine into the maternal circulation, inducing widespread endothelial dysfunction that 
heralds the classic manifestations of the disease.
It has been widely accepted that serving with PE prevention much better than treatment, so early 
detection and risk identifi cation from those related woman group might have been mostly considering 
effort into health strategic campaign. With this regard clearly biomarker assesment has posed its 
position to be required interestingly. The ability to predict PE would be a major advance in maternal-
fetal medicine, it is known well that several proposed biomarkers comprising angiogenic markers 
(sFli-1,VEGF,PlGF and  sEng) in maternal circulation precede the clinical onset of PE by severalweeks 
to months, Placental Protein-13 is a member of the galectin family, predominantly expressed by the 
syncytiotrophoblasts, that is involved in normal implantation and placental vascular development, 
Pregnancy-Associated Plasma Protein A is a peptidase produced by syncitiotrophoblast with hydrolytic 
activity for insulin-like growth factor- binding proteins, and Free Fetal Nucleic-Acids circulate in the 
maternal blood5-8.
What would be needed largely nowadays for tropical, coastal and developing state not sophisticated 
and expensively aboved sort of methods but much more likely such a test of affordable, good accuracy 
and accountability. However, it could be not other than combined test comprising simply found history 
taking of risk factors (i.e. elderly primigravida less than 35 years old, genetic, obesity, twin etc.), BMI, 
MAP and uterine artery Doppler velocimetry (UADV). Although it was never reached the best prediction 
result, only a little bit lower compared to those what Espinoza et al said in their study as the prediction 
sensitivities of maternal plasma PlGF concentration, abnormal UADV, and the combination of these 
test were 61.35% and 27%, respectively. His research group conducted a prospective study of 3296 
women to determine the role of UADV, maternal plasma PlGF among others, where sample collection 
and UADV were performed between 22 and 26 weeks. 6,7
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